Company Profile

1779

1779 · HK

Industry: Pharmaceuticals
Exchange: HK

Current Price

HK$96.06

Jun 3, 2026 close

Fair Buy

≤ HK$54

Margin-of-safety entry

Baillie Growth Score

37/100

Weak

Intrinsic Value · Three-Tier Range Current price HK$96.06 · Within the fair intrinsic-value range

Current price HK$96.06

Composite valuation range · conservative HK$57–HK$78 / fair HK$81–HK$110 / optimistic HK$120–HK$163. At HK$96.06, Within the fair intrinsic-value range.

Research on this stock

LongBio Pharma

1779 · HK

Watch

LongBio Pharma-B Vertical and Horizontal Analysis

LongBio Pharma is a China 18A innovative-drug IPO candidate whose core anti-IgE antibody LP-003 is nearing BLA submission. As of 2026-06-03, it had not yet started trading, and the HK$96.06 offer price already reflected substantial success expectations while standing well above a conservative intrinsic value of HK$67.4. Rating Watch: a zero-revenue, zero-profit biotech with value highly concentrated in LP-003 and an ideal buy price at or below HK$54.

Pharmaceuticals Baillie 37 Jun 3, 2026

About the company

Company overview coming soon.

Background

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.